SCHEMBL5492736

SCHEMBL5492736

CCOC(=O)CC(CC1CC1)C[N+](=O)[O-]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.33
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
CNR2 P34972 1/20 0.31
ALDH1A1 P00352 3/20 0.31
SMYD3 Q9H7B4 1/20 0.31
TRPA1 O75762 1/20 0.31
CYP3A4 P08684 2/20 0.31
ALOX15 P16050 2/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
UGT2B7 P16662 2/20 0.30
POLB P06746 1/20 0.30
DGAT1 O75907 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302076 0.78 MAPT (0.38) CYP2D6MAPTKDM4ELMNAMGAM
SCHEMBL1664773 0.78 MAPT (0.38) MAPTKDM4ELMNAMGAMGAA
SCHEMBL14535008 0.78 CTSK (0.35)
SCHEMBL5497112 0.78 ANPEP (0.34) LMNAKMT2A
SCHEMBL2912395 0.77 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA
SCHEMBL1410099 0.77 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA
SCHEMBL1228652 0.77 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA
SCHEMBL29021009 0.77 MAPT (0.37) MAPTKDM4ELMNAMGAMGAA
SCHEMBL232250 0.76 CYP2D6 (0.46) CYP2D6LMNAKMT2AMGAMGAA
SCHEMBL5105701 0.76 TSHR (0.41) MAPTKDM4ELMNAKMT2AMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0937032-B1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER LAMBERT CO (US) 2007-05-09 EP disclosed
US-6153650-A TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, NEUROPATHOLOGICAL DISORDERS, INFLAMMATION, AND GASTROINTESTINAL DAMAGE. WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
EP-0937032-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 1999-08-25 EP disclosed
WO-1998017627-A1 SUBSTITUTED GAMMA AMINOBUTYRIC ACIDS AS PHARMACEUTICAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-04-30 WO disclosed